Risk of selected gastrointestinal and hepatic toxicities in cancer patients treated with nintedanib: a meta-analysis.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Future Oncology

• Publication date

  2016-06-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.2217/fon-2016-0067PMID 27301454
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Risk of elevated transaminases in non-small cell lung cancer (NSCLC) patients treated with erlotinib, gefitinib and afatinib: a meta-analysis

  2016cited by this paper
• Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.

  2016cited by this paper
• Risk of oral and gastrointestinal mucosal injury in patients with solid tumors treated with ramucirumab: a systematic review and meta-analysis

  2015cited by this paper
• Risk of elevated transaminases in cancer patients treated with immune checkpoint inhibitors: a meta-analysis

  2015cited by this paper
• Nintedanib: A Review of Its Use in Patients with Idiopathic Pulmonary Fibrosis

  2015cited by this paper
• Analysis of patient-reported outcomes from the LUME-Lung 1 trial: a randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer.

  2015cited by this paper
• A randomised, phase II study of nintedanib or sunitinib in previously untreated patients with advanced renal cell cancer: 3-year results

  2015cited by this paper
• Risk of fatigue and hepatic and metabolic toxicities in patients with solid tumors treated with everolimus: a meta-analysis.

  2015cited by this paper
• A phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patients.

  2015cited by this paper
• Randomized phase II study of nintedanib in metastatic castration-resistant prostate cancer postdocetaxel

  2014cited by this paper
• Antifibrotic and Anti-inflammatory Activity of the Tyrosine Kinase Inhibitor Nintedanib in Experimental Models of Lung Fibrosis

  2014cited by this paper
• Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.

  2014cited by this paper
• Risk of cardiovascular toxicities in patients with solid tumors treated with sunitinib, axitinib, cediranib or regorafenib: an updated systematic review and comparative meta-analysis.

  2014cited by this paper
• Randomized Phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer.

  2014cited by this paper
• Does the use of lapatinib increase the risk of fatigue and hepatic toxicities in patients with solid tumors? A critical literature review and meta-analysis

  2014cited by this paper
• Adjuvant systemic treatment for elderly breast cancer patients; addressing safety concerns

  2014cited by this paper
• Hepatotoxicity of Tyrosine Kinase Inhibitors: Clinical and Regulatory Perspectives

  2013cited by this paper
• Reducing lung function decline in patients with idiopathic pulmonary fibrosis: potential of nintedanib

  2013cited by this paper
• BIBF 1120 (Nintedanib), a Triple Angiokinase Inhibitor, Induces Hypoxia but not EMT and Blocks Progression of Preclinical Models of Lung and Pancreatic Cancer

  2013cited by this paper
• BIBF 1120/nintedanib: a new triple angiokinase inhibitor-directed therapy in patients with non-small cell lung cancer

  2013cited by this paper
• Tobacco cessation and control a decade later: American society of clinical oncology policy statement update.

  2013cited by this paper
• Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer.

  2011cited by this paper
• A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer.

  2011cited by this paper
• Signal transduction pathways involved in drug-induced liver injury.

  2010cited by this paper
• Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement

  2009cited by this paper
• The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway.

  2008cited by this paper
• Cancer chemotherapy-induced diarrhoea and constipation: mechanisms of damage and prevention strategies

  2006cited by this paper
• Are patients with elevated liver tests at increased risk of drug-induced liver injury?

  2004cited by this paper
• Recommended guidelines for the treatment of chemotherapy-induced diarrhea.

  1998cited by this paper

• Survival impact and safety comparison of pirfenidone and nintedanib for idiopathic pulmonary fibrosis: A meta-analysis

  2025cites this paper
• Exploring the top 30 drugs associated with drug-induced constipation based on the FDA adverse event reporting system

  2024cites this paper
• Nebulized inhalation of nintedanib-loaded biomimetic nano-liposomes attenuated bleomycin-induced interstitial lung fibrosis in mice

  2024cites this paper
• Targeted Therapies in the Management of Well-Differentiated Digestive and Lung Neuroendocrine Neoplasms

  2020cites this paper
• Nintedanib in patients with systemic sclerosis-associated interstitial lung disease: A Japanese population analysis of the SENSCIS trial

  2020cites this paper
• Histological evaluation of nintedanib in non-alcoholic steatohepatitis mice.

  2019cites this paper
• Emerging multitarget tyrosine kinase inhibitors in the treatment of neuroendocrine neoplasms.

  2018cites this paper